Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies that modulate molecular ...

Hypertrophic cardiomyopathy (HCM) is the most common hereditary heart disease. It causes the left ventricle to thicken, the ...

The FDA has granted fast track designation to MT-125 for the treatment of patients with glioblastoma. The U.S. Food and Drug ...

MT-125, a dual small-molecule inhibitor, received FDA fast track designation for glioblastoma, facilitating expedited drug ...

Bristol Myers Squibb launches Kopozgo in India for obstructive hypertrophic cardiomyopathy treatment, expanding therapeutic offerings.

In a phase 2b trial, danicamtiv, a novel cardiac myosin activator, was well tolerated and associated with improved heart ...

Bristol Myers Squibb (BMS) on Wednesday announced the launch of Kopozgo (Mavacamten), an oral, selective cardiac myosin ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is one of the best small cap stocks with the highest upside. H.C. Wainwright ...

Maintaining a good level of physical fitness is important. However, it can be difficult to determine what fitness entails.

During the development of hypertrophy, cardiac myocytes increase organization of the sarcomere, a highly ordered contractile unit in striated muscle cells. Several hypertrophic agonists, such as ...

Event-native data platform innovator Kurrent today announced the release of KurrentDB 25.1, delivering its most developer-friendly event sourcing database yet and removing traditional barriers that ...